|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter Belden offers unique insight into strategies that can be applied to weather the turbulent times ahead and ensure a reliable supply of critical drug products to patients, and explores how sustainability and integrity can be attained with the right packaging and supply chain solutions.
|
|
|
Joseph M. Palumbo, MD, says addressing Parkinson’s via the inflammatory pathway offers a unique perspective that was virtually unheard of only 10 years ago.
|
|
|
Luminita Moraru, MSc, explains how the medical devices industry has grown and is expanding daily and presents the key steps that need consideration when assessing breathing devices.
|
|
|
Sesha Neervannan, PhD, Chief Operating Officer of Tarsus, discusses the company’s innovative approach to creating a new treatment category for eyelid disease and their strategic focus on advancing other treatments in their pipeline.
|
|
|
|
|
|
|
|
|

Fortis Life Sciences offers world-class reagents, tools, materials, and custom services with a best-in-class customer experience for our customers in the biopharma industry. Through our brand nanoComposix, we provide precisely engineered and highly characterized nanomaterials to a global customer base. nanoComposix is an ISO 13485 (2016)-Certified*, FDA-registered developer and contract manufacturer with a nanomaterial product portfolio containing hundreds of variants engineered to address the unique challenges presented by our customers. Our products and CDMO services are backed by technical teams with extensive expertise in nanotechnology, biology, chemistry, physics, and optics. Click here for more.
|
|
|
|
|
|
 |
|
Quantoom Biosciences recently announced a new collaboration with Stevanato Group, a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, with the goal of….
|
|
 |
|
First Wave to develop and repurpose Capeserod for gastrointestinal (GI) indications based on AI-empowered analyses, expanding the company’s GI-focused pipeline….
|
|
 |
|
Hepion Pharmaceuticals, Inc. recently announced positive results from a translational research study in which Hepion’s lead drug candidate, rencofilstat, was administered to diseased human lung tissue from….
|
|
 |
|
Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)….
|
|
|
|
|
|
|
|
 |
|
Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on
|
|
 |
|
In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….
|
|
|
|
|
|
|
|
 |
|
Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …
|
|
 |
|
Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …
|
|
 |
|
Ensuring sufficient solubility is critical to the success of small molecule drugs. An active pharmaceutical ingredient (API) must be absorbed by the body and enter the systemic circulation to deliver the desired therapeutic effect. Many APIs, however, suffer from low …
|
|
 |
|
In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and skin penetration enhancers.
Considerations include the …
|
|
|
|
|
Upcoming eNewsletter Features:
September 27 – Analytical Testing
October 4 – Formulation Development
|
|
|
|
|
|
|
|